Tumors<unk>  is used for the treatment of growth hormone producing tumors (acromegaly and gigantism), when surgery is contraindicated, pituitary tumors that secrete thyroid-stimulating hormone (thyrotropinoma), diarrhea and flushing episodes associated with carcinoid syndrome, and diarrhea in people with vasoactive intestinal peptide-secreting tumors (VIPomas).<unk>  is also used in mild cases of glucagonoma when surgery is not an option. Bleeding esophageal varices<unk>  is often given as an infusion for management of acute hemorrhage from esophageal varices in liver cirrhosis on the basis that it reduces portal venous pressure, though current evidence suggests that this effect is transient and does not improve survival. Radiolabeling<unk>  is used in nuclear medicine imaging by labeling with indium-111 <unk> reoscan) to noninvasively image neuroendocrine and other tumours expressing somatostatin receptors. More recently, it has been radiolabeled with carbon-11 as well as gallium-68 (using edotreotide), enabling imaging with positron emission tomography (PET), which provides higher resolution and sensitivity.<unk>  (usually as the derivative edotreotide or DOTATOC) can also be labeled with a variety of therapeutic radionuclides, such as yttrium-90 or lutetium-177, to enable peptide receptor radionuclide therapy (PRRT) for the treatment of unresectable neuroendocrine tumours. Acromegaly<unk>  can also be used in the treatment of acromegaly, a disorder of excessive growth hormone (GH).<unk> , being a somatostatin analog, inhibits the release of GH from the pituitary gland through a process normally involved in negative feedback. In June 2020, Mycapssa<unk>  was approved for medical use in the United States with an indication for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with<unk>  or lanreotide. Mycapssa is the first and only oral somatostatin analog (SSA) approved by the FDA. Gastrointestinal fistulae<unk>  helps in management of the fistula by reducing gastrointestinal secretions and inhibiting gastrointestinal motility, thus controlling and reducing its output. The value in healing intestinal fistulas is yet to be proven and routine use is limited because of the side effects. Hypoglycemia<unk>  is also used in the treatment of refractory hypoglycemia in neonates and sulphonylurea-induced hypoglycemia in adults. It is useful in overdose management of sulfonylurea type antidiabetic medications, when recurrent or refractory to parenteral dextrose. Mechanism of action is the suppression of insulin secretion.
Octreotide
Edotreotide
Lanreotide
Fertirelin
Metoclopramide
Tenatoprazole
Leuprorelin
Rabeprazole